TD Cowen Reiterates Buy Rating on DexCom (DXCM)

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $100.00 price target on DexCom (NASDAQ: DXCM).

The analyst commented, "DXCM reported 3Q results which were slightly ahead of Street revenue and EPS expectations. Importantly, management's commentary suggests that US market headwinds may have peaked in 3Q and should moderate going forward. This, combined with progress in the company's pipeline (Stelo launch, 15-day G7 submission), drives our optimism towards improving performances in the coming quarters."

For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.

Shares of DexCom closed at $74.85 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades Nike (NKE) to Buy
• AI Search Engineers Announces Three Q4 AI and Media Award Program Recipients as Custom AI-Optimized Websites, Schema Markup, Press Releases, and Feature Articles Deploy Oct. 1
• William Blair: 'We expect this news to add to an already burdensome (and ongoing) overhang for both EFX and TRU shares'